Table 1. Patient breakdown.
| Presumptive Cases | Diagnosis | Enrolled for treatment | |||||||
|---|---|---|---|---|---|---|---|---|---|
| RV & RVII | SSF | NCE | RV & RVII | SSF | NCE | RV & RVII | SSF | NCE | |
| New cases | 3,430 | 48,482 | 35,881 | 112 | 2,141 | 1,283 | 38 | 1,129 | 771 |
| Other high risk groups | 8,691 | 20,334 | 14,092 | 1,743 | 5,590 | 2,875 | 917 | 4,031 | 2,297 |
|
Funding round total (%)a |
12,121 (9) | 68,816 (53) |
49,973 (38) |
1,855 (14) |
7,731 (56) |
4,158 (30) |
955 (10) |
5,160 (56) |
3,068 (34) |
|
Cumulative Total |
130,910 | 13,744 | 9,183 | ||||||
Round V (RV) funding began on October 1, 2007 and ended on June 30, 2010, and Round VII (RVII) began on October 1, 2008 and ended on June 30, 2010. Single-stream funding (SSF) began on July 1, 2010 and ended on June 30, 2013. The no cost extension (NCE) period began on July 1, 2013 and ended on June 30, 2014.
a Percentage from cumulative total.